First Time Loading...
C

Clarus Therapeutics Holdings Inc
NASDAQ:CRXT

Watchlist Manager
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Watchlist
Price: 0.021 USD -19.54%
Updated: Jun 10, 2024

Clarus Therapeutics Holdings Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clarus Therapeutics Holdings Inc
Accounts Receivables Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Accounts Receivables
$6.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Receivables
$14.9B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Receivables
$9.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
18%
Pfizer Inc
NYSE:PFE
Accounts Receivables
$11B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Accounts Receivables
$11.4B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accounts Receivables
$7.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%

See Also

What is Clarus Therapeutics Holdings Inc's Accounts Receivables?
Accounts Receivables
6.3m USD

Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Accounts Receivables amounts to 6.3m USD.

What is Clarus Therapeutics Holdings Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
44%

Over the last year, the Accounts Receivables growth was 44%.